Coral Laboratories Ltd
NSE: BSE: 524506
₹443.70
(1.04%)
Wed, 11 Mar 2026, 05:30 am
Market Cap1.59B
PE Ratio11.33
Dividend0.34
Health Technology
Pharmaceuticals: Other
24.5KCoral Laboratories Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are thoroughly covered by earnings (10x coverage).
- Coral Laboratories's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Coral Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Coral Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Coral Laboratories is profitable, therefore cash runway is not a concern.
- Coral Laboratories is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 16.2x debt.
- Coral Laboratories's cash and other short term assets cover its long term commitments.
- Interest payments on debt are well covered by earnings (EBIT is 56.5x coverage).
- Coral Laboratories's level of debt (5.1%) compared to net worth is satisfactory (less than 40%).
- Operating cash flow is negative therefore debt is not well covered.
- The level of debt compared to net worth has increased over the past 5 years (2.3% vs 5.1% today).
- High level of physical assets or inventory.
management
- The tenure for the Coral Laboratories board of directors is about average.
- Girish's remuneration is lower than average for companies of similar size in India.
- Girish's compensation has been consistent with company performance over the past year, both up more than 20%.
misc
- Coral Laboratories is not covered by any analysts.
- Coral Laboratories has significant price volatility in the past 3 months.
past
- Coral Laboratories's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Coral Laboratories's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
- Coral Laboratories used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Coral Laboratories's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Coral Laboratories has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Coral Laboratories's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- Coral Laboratories is good value based on assets compared to the IN Pharmaceuticals industry average.
- Coral Laboratories is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Coral Laboratories is good value based on earnings compared to the India market.
- 524506 outperformed the Market in India which returned -14.5% over the past year.
- BSE:524506 is up 37.7% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524506 is up 37.7% outperforming the market in India which returned 8% over the past month.
- Coral Laboratories's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Coral Laboratories's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- 524506 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800